Opinion

Justin Taylor: We show that E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies.

Photo taken from: Justin Taylor/Twitter

Oct 10, 2023, 21:35

Justin Taylor: We show that E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies.

Justin Taylor, Assistant Professor at UM Sylvester Comprehensive Cancer Center and Principle Investigator at the Taylor Lab, made the following post on Twitter:

“Excited to see this paper in print Leukemia Journal! Many preclinical studies using RBM39 molecular glue degraders e.g indisulam. We show that E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies.

Great collaboration between Memorial Sloan Kettering Cancer Center and Sylvester Comprehensive Cancer Center! Led by twitter-less Drs. Jan Bewersdorf and Eytan Stein, Abdel Wahab Lab, Lu Lab, Namrata Chandhok, Justin Watts and many others. Access to the full text here.”

Source: Justin Taylor/Twitter

Abdel-Wahab Lab cancer Eytan Stein Jan Bewersdorf Justin Taylor Justin Watts Leukemia Journal Lu Lab Memorial Sloan Kettering Cancer Center Namrata Chandhok OncoDaily Oncology Sylvester Comprehensive Cancer Center

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage